Bracco Gains EU Approval to Expand Contrast Agent Use in Infants
Event summary
- The European Commission approved an extension of the Marketing Authorisation for Bracco’s Vueway® (gadopiclenol) to include pediatric patients under 2 years of age, effective January 23, 2026.
- The approval followed a positive opinion from the CHMP and a recommendation from the EMA.
- Vueway® is a macrocyclic gadolinium-based contrast agent approved in 36 countries, previously approved for use in adults and children over 2 years old.
- Clinical studies (GDX-44-015) demonstrated Vueway® can achieve comparable diagnostic efficacy at half the gadolinium dose of gadobutrol.
The big picture
This approval underscores the increasing scrutiny and refinement of contrast agent usage, particularly in vulnerable patient populations. The ability to reduce gadolinium exposure while maintaining diagnostic efficacy is a key differentiator in a market facing growing concerns about gadolinium deposition. Bracco’s collaboration with Guerbet creates a complex dynamic, balancing shared intellectual property with independent commercialization strategies.
What we're watching
- Adoption Rate
- The speed at which pediatricians and radiologists adopt Vueway® for younger patients will determine the extent of Bracco’s revenue gains in this new segment.
- Competitive Response
- Guerbet, with whom Bracco has a manufacturing collaboration, may accelerate development of competing products or strategies to maintain its position in the contrast agent market.
- Liability Risk
- Long-term monitoring of patient outcomes in this expanded pediatric population will be crucial to identify and mitigate any unforeseen adverse effects related to gadolinium retention.
Related topics